CD40L GVAX
Alternative Names: Autologous tumour cell-based vaccine; Bystander vaccine; Bystander-based autologous tumour cell vaccine; CD40LGVAX; Dendristim vaccine; GM-CSF/CD40L; GM.CD40L; GM.CD40L bystander vaccine; hCD40L/hGM-CSFLatest Information Update: 27 Nov 2023
At a glance
- Originator University of South Florida
- Developer H. Lee Moffitt Cancer Center and Research Institute
- Class Antineoplastics; Cancer vaccines; CD antigens; Cell therapies; Gene therapies; Granulocyte-macrophage colony-stimulating factors; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- Phase II Lung cancer; Malignant melanoma
- No development reported Myelodysplastic syndromes
Most Recent Events
- 20 Nov 2023 Cellular Biomedicine Group is now called AbelZeta Pharma
- 28 Dec 2021 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Combination therapy, Second-line therapy or greater) in USA (Intradermal, Injection)
- 11 Dec 2019 CD40L GVAX is still in phase I trials for Myelodysplastic-syndromes (Combination therapy, Second-line therapy or greater) in USA (Intradermal, Injection) (NCT00840931)